North America Startup Funding Rounds
Startups raising capital across North America. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 2,318 All time
- Disclosed funding
- $225.3B 1925 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| D DeepSeeCompany profile Provides agentic AI technology for financial services and capital markets firms to automate post-trade operations Provides agentic AI technology for financial services and capital markets firms to automate post-trade operations | Undisclosed | StrategicUndisclosed | Fintech | United States | Investors | |
| PP Develops Voice AI for quick-service restaurant drive-thrus | $10M | Undisclosed | Foodtech | United States | Investors | |
| VE Valinor EnterprisesCompany profile Builds and buys critical defense and government technology solutions Builds and buys critical defense and government technology solutions | $54M | Series A | Defense tech | United States | Investors | |
| SA Spangle AICompany profile Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce | $15M | Series A | AI | United States | Investors | |
| ED Enhanced Digital Group Inc.Company profile Provides derivatives solutions in the digital asset space for institutional clients Provides derivatives solutions in the digital asset space for institutional clients | Undisclosed | Series A | Fintech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
| F Medical imaging data management and analysis platform | $27.5M | Undisclosed | Healthtech | United States | Investors | |
| E EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Y Combinator (YC)
Tractian, Blacksmith, Greptile
131rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
102rounds20led - 3General Catalyst
Tractian, Different, Baba
72rounds8led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
59rounds0led - 5Khosla Ventures
Arda Industries, Tolan
59rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.